A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL
Reid W. Merryman(Harvard University), Viktor A. Adalsteinsson(Broad Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Timothy Blewett(Broad Institute), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Katherine Antel(University of Cape Town), Mark A. Murakami(Harvard University), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Philippe Armand(Harvard University), Hyun Hwan An(Dana-Farber Cancer Institute), Justin Rhoades(Broad Institute), Kan Xiong(Broad Institute), Ju Chen(Broad Institute), Sainetra Sridhar(Broad Institute), A. Crnjac(Broad Institute), Lillian Guerrero(Dana-Farber Cancer Institute), Mikaela M. McDonough(Dana-Farber Cancer Institute), Robert Redd(Harvard University)
Cited by 2
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|1k